New publication on how cfRNA and AI are advancing LBx

New Publication - cfRNA and AI -GTC

GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune Biomarkers”. This study explores the potential of cell-free RNA (cfRNA) and AI as valuable components of liquid biopsy for evaluating the host immune system and predicting disease markers. 

The study reveals key findings: 

1. Mutation Profile and Chromosomal Abnormalities: 

   – Using a targeted RNA panel significantly more mutations were detected using cfRNA compared to cfDNA. 

   – cfRNA analysis provides comprehensive information on mutation profiling, chromosomal structural abnormalities, and fusion genes, increasing sensitivity and specificity for detecting minimal residual disease (MRD). 

2. Immune Biomarkers and Host Response: 

   – cfRNA evaluation reflects the expression levels of important genes associated with specific cancers and the host immune response. 

   – cfRNA can provide information comparable to flow cytometry analysis of hematologic neoplasms and can evaluate immune system markers in various diseases. 

3. Clinical Applications and Future Directions: 

   – Integrating cfRNA and cfDNA analysis enhances liquid biopsy capabilities. 

   – Machine learning algorithms can distinguish between normal and diseased states, predict therapy response, and develop specific diagnostic models. 

   – Larger studies are needed to confirm these findings and establish clinical applications for cfRNA-based liquid biopsy. 

This study has significant implications for liquid biopsy research and clinical practice.  


Τumor-informed vs Tumor-naïve

Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA) (also called circulating tumor DNA,

Read More »

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends